Synergy CHC Corp. (SNYR)·Q2 2025 Earnings Summary
Executive Summary
- Q2 2025 delivered the tenth consecutive profitable quarter: EPS of $0.17 (+86% y/y), net income of $1.47M (+125% y/y), and EBITDA of $3.80M (+136% y/y), supported by high-margin license revenue and a gain on settlement of notes payable .
- Revenue of $8.13M grew 1% y/y but missed S&P Global consensus of $10.80M; EPS beat consensus $0.08 as reported $0.17 benefited from licensing mix and the notes settlement gain *.
- Gross margin expanded to 76.7% (+720 bps y/y) on licensing mix; operating expenses rose with public-company costs; operating income ticked up 2.5% y/y to $1.62M .
- Strategic catalysts: $20M debt refinancing extends maturities to 2029 (interest-only through 2025), major retail/distribution wins (Core-Mark national authorization; Walmart Canada Q4 launches), and international expansion (UAE/Turkey licensing; Mexico subsidiary shipping to Costco/Walmart) .
- RTD beverages ramp shifted later: Q2 RTD revenue ~$0.15M (Amazon), with broader contributions expected in Q3–Q4 following the refinancing and distribution build-out; licensing revenue likely lumpy near term .
What Went Well and What Went Wrong
What Went Well
- Tenth straight profitable quarter; CEO: “Revenue, gross profit, net income and earnings per share all grew year-over-year…” .
- Margin strength: gross margin 76.7% (+720 bps y/y), driven by $1.4M license revenue and mix .
- Balance sheet/capital structure: $20M term loan due 2029 (interest-only through 2025) enhanced flexibility; CEO: refinancing “extends our maturity profile, enhances financial flexibility and supports our long-term growth strategy” .
What Went Wrong
- Top-line below Street: $8.13M vs $10.80M consensus; product sales down y/y with licensing mix masking underlying softness; operating expenses up 16% y/y on public-company costs *.
- RTD revenue below prior commentary ($2M expected in Q2 per Q1 call) as ramp shifted post-refinancing; Q2 RTD Amazon revenue ~$0.148M .
- Higher interest burden ($2.11M) offset operating gains; EPS benefited from a $2.15M gain on settlement of notes payable, highlighting non-operating volatility .
Financial Results
Headline P&L and Margins (y/y, q/q, vs estimates)
Segment/Revenue Mix
Operating Expenses and Selected KPIs
Actual vs S&P Global Consensus (Q2 2025)
Note: Asterisks indicate values retrieved from S&P Global; comparisons use company-reported actuals.
Values retrieved from S&P Global.*
Drivers: revenue shortfall vs consensus amid product sales softness; EPS/EBITDA upside aided by high-margin licensing and the $2.15M gain on settlement of notes payable offsetting high interest expense .
Guidance Changes
No formal quantitative guidance provided for total revenue, margins, opex lines, OI&E, tax rate, or dividends in Q2 materials .
Earnings Call Themes & Trends
Management Commentary
- CEO (Q2 PR): “We are pleased to report another strong quarter, marking our tenth consecutive quarter of profitability.”
- CEO (Q2 PR): “We successfully completed a $20 million debt refinancing… extends our maturity profile, enhances financial flexibility and supports our long-term growth strategy.”
- CFO (Q2 call): “Operating expenses… were primarily due to incremental costs associated with being a public company.”
- CEO (Q2 call): “Core-Mark… granted national item authorization… unlocking access to sell to over 50,000 retail locations… Walmart Canada will be launching two SKUs nationally in Q4.”
- CEO (Q2 call): On licensing cadence: “We don’t really expect anything in the third quarter… it might get a little bumpy.”
Q&A Highlights
- RTD revenue realization: ~$148k in Q2 from Amazon; broader retail contributions mostly to come in Q3–Q4 post-refinancing and distribution build-out .
- Licensing economics: Near-100% gross margin implied; cadence likely “lumpy”; no Q3 license revenue expected .
- Expenses: Higher professional/legal fees in Q2 tied to public-company status; selling/operations “in line” .
- Mexico: Revenue (not licensing) via own footprint; shipping to Costco/Walmart Mexico late Q3/early Q4 .
- Flat Tummy: “Staying pretty steady”; no new developments in Q2 .
Estimates Context
- EPS: $0.17 actual vs $0.08 S&P Global consensus → Bold beat driven by mix and non-operating gain *.
- Revenue: $8.13M actual vs $10.80M S&P Global consensus → Miss amid product sales softness; license revenue provided margin support *.
- EBITDA: $3.80M actual vs $2.27M S&P Global consensus → Beat on high-margin licensing and notes settlement gain offsetting interest expense *.
Values retrieved from S&P Global.*
Where estimates may adjust: Street likely revises near-term revenue lower (RTD ramp later; Q3 licensing minimal) and raises margin/EBITDA assumptions due to licensing mix and capital structure relief (interest-only through 2025) .
Key Takeaways for Investors
- Mix-driven margin expansion with licensing now a meaningful contributor ($1.4M in Q2) supports EBITDA and EPS resilience despite top-line variability .
- The $20M refinancing (interest-only 2025; maturity to 2029) is a critical de-risking step that improves near-term FCF and supports H2 growth initiatives .
- RTD ramp is real but back-half weighted; Core-Mark authorization, Canadian pharmacy distribution (McKesson), and Walmart Canada Q4 placements should be monitored as near-term catalysts .
- Q2 EPS outperformance benefited from a $2.15M gain on settlement of notes payable; normalize non-operating items when modeling run-rate earnings quality .
- Working capital inflected to a $12.4M surplus by 6/30 (from a $(1.12)M deficit at year-end), providing operational flexibility for H2 execution .
- Expect estimate dispersion: license revenue lumpy (no Q3), RTD scaling in Q3–Q4; shift modeling toward margin/EBITDA resilience vs near-term revenue growth .
- Post-earnings equity financing ($4.375M gross) adds incremental liquidity for growth; watch dilution vs growth ROI and deployment pace into RTD and international expansion .